AstraZeneca (NYSE:AZN) said today that the FDA approved its once-weekly exenatide drug in a single-dose auto-injector for adults with Type II diabetes whose blood sugar is uncontrolled on one or more oral drugs.
The company’s drug, Bydureon, is formulated with a continuous-release microsphere delivery system designed to provide consistent levels of exenatide, according to AstraZeneca, to reduce blood sugar levels in people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo appeared first on MassDevice.